De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

American Journal of Hematology

Volumn 89, Issue 11, 2014, Pages E193-E199

  Hasserjian, Robert Paul ^a   Campigotto, Federico ^b   Klepeis, Veronica ^a   Fu, Bin ^c   Wang, Sa A ^c   Bueso Ramos, Carlos ^c   Cascio, Michael Joseph ^d   Rogers, Heesun Joyce ^e   Hsi, Eric Darryl ^e   Soderquist, Craig ^f   Bagg, Adam ^f   Yan, Jiong ^g   Ochs, Rachel ^g   Orazi, Attilio ^g   Moore, Frank ^h   Mahmoud, Amer ^h   George, Tracy Irene ^h   Foucar, Kathryn ^h   Odem, Jamie ⁱ   Booth, Cassie ⁱ   Morice, William ⁱ   DeAngelo, Daniel J ^b   Steensma, David ^b   Stone, Richard Maury ^b   Neuberg, Donna ^b   Arber, Daniel Alan ^d   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; CYTOTOXIC AGENT; FLT3 LIGAND; GROWTH FACTOR; HEMOGLOBIN; HYDROXYUREA; NUCLEOPHOSMIN; STEROID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOGENETICS; DE NOVO ACUTE MYELOID LEUKEMIA; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK PATIENT; KARYOTYPE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 85006355305     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23808     Document Type: Article

References (29)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.
2. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90:2969–2977.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
4. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
5. Estey E, Pierce S, Kantarjian H, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993;11(Suppl 2):59–63.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
7. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840–4845.
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562–569.
9. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study. Blood 2002;100:3869–3876.
10. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol 2008;35:430–438.
11. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
12. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008. pp 88–93.
13. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 20120;30:820–829.
14. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
15. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2008. pp 124–126.
16. Breccia M, Latagliata R, Carmosino I, et al. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: Identification of subgroups with different survival. Acta Haematol 2007;117:221–225.
17. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670–2677.
18. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598–605.
19. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
20. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009;113:1906–1908.
21. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 2010;116:3622–3626.
22. Strupp C, Gattermann N, Giagounidis A, et al. Refractory anemia with excess of blasts in transformation: Analysis of reclassification according to the WHO proposals. Leuk Res 2003;27:397–404.
23. Okuyama N, Sperr WR, Kadar K, et al. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study. Leuk Res 2013;37:862–867.
24. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003;119:672–680.
25. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:1596–1604.
26. Singh ZN, Huo D, Anastasi J, et al. Therapy-related myelodysplastic syndrome: Morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007;127:197–205.
27. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: Results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256–265.
28. Pleyer L, Stauder R, Burgstaller S, et al. Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 2013;6:32.
29. van der Helm LH, Veeger NJ, Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res 2013;37:877–882.